Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Use of sildenafil to manage preeclampsia: effect on fetal blood flow and fetal weight
FY 2020-21
Summary
Preeclampsia (PE) is a syndrome present in pregnant women, and creates persistent vasoconstriction. PE affects 3-8% of pregnancies in Western countries. While deaths by PE are rare in developed nations, the World Health Organization states that PE and eclampsia (when PE patients develop seizures) comprise 14% of maternal deaths worldwide. The resulting vasoconstriction from PE reduces placental blood flow, causing fetal growth restriction (FGR). Antihypertensives are a common treatment for PE, with labetalol as a drug commonly used. However, another antihypertensive, sildenafil, initially used to treat erectile dysfunction, also has the potential to be a viable treatment of PE. By causing vasodilation, antihypertensives like sildenafil can reverse the vasoconstriction of PE, increase placental blood flow, and mitigate the effects of FGR: the phenomenon this study will explore. This study will be multi-institute, randomised, double-blind, non-crossover, and fixed-dose. 100 pregnant women will be recruited between the ages of 25 and 35 professionally diagnosed with PE from one the ten largest maternity wards in Toronto. Women will be randomly allocated by computer to 50mg of sildenafil every eight hours or the current treatment of 300mg Labetalol twice daily in a 1:1 ratio. Fetal blood flow will be measured by Doppler Ultrasound, and fetal weight by normal ultrasound. The study will end upon delivery of the baby. The antihypertensive drug sildenafil has the potential to be another drug intervention usable to manage PE and FGR and provide another avenue of treatment for pregnant women with such a debilitating disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449613
Name
Ke Danny (Yu Jia)
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Use of sildenafil to manage preeclampsia: effect on fetal blood flow and fetal weight
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical; Doppler Ultrasound; Fetal Blood Flow; Fetal Weight; Preeclampsia; Pregnancy; Sildenafil
Abstract
Preeclampsia (PE) is a syndrome present in pregnant women, and creates persistent vasoconstriction. PE affects 3-8% of pregnancies in Western countries. While deaths by PE are rare in developed nations, the World Health Organization states that PE and eclampsia (when PE patients develop seizures) comprise 14% of maternal deaths worldwide. The resulting vasoconstriction from PE reduces placental blood flow, causing fetal growth restriction (FGR). Antihypertensives are a common treatment for PE, with labetalol as a drug commonly used. However, another antihypertensive, sildenafil, initially used to treat erectile dysfunction, also has the potential to be a viable treatment of PE. By causing vasodilation, antihypertensives like sildenafil can reverse the vasoconstriction of PE, increase placental blood flow, and mitigate the effects of FGR: the phenomenon this study will explore. This study will be multi-institute, randomised, double-blind, non-crossover, and fixed-dose. 100 pregnant women will be recruited between the ages of 25 and 35 professionally diagnosed with PE from one the ten largest maternity wards in Toronto. Women will be randomly allocated by computer to 50mg of sildenafil every eight hours or the current treatment of 300mg Labetalol twice daily in a 1:1 ratio. Fetal blood flow will be measured by Doppler Ultrasound, and fetal weight by normal ultrasound. The study will end upon delivery of the baby. The antihypertensive drug sildenafil has the potential to be another drug intervention usable to manage PE and FGR and provide another avenue of treatment for pregnant women with such a debilitating disease.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ke, Danny (Yu Jia)
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~